Highly Efficient PD-1-Targeted CRISPR-Cas9 for Tumor-Infiltrating Lymphocyte-Based Adoptive T Cell Therapy

Non-viral/plasmid-based programmed cell death protein 1 (PD-1) knockout was carried out immediately prior to the traditional 14-day tumor-infiltrating lymphocytes-based ACT rapid expansion protocol.